Drug Information

Drug General Information
Drug ID
D00GOV
Former ID
DNCL003443
Drug Name
Nivolumab
Drug Type
Monoclonal antibody
Indication B-RAF mutation positive metastatic melanoma [ICD9: 172; ICD10:C43] Approved [542358], [551486]
Advanced non-small cell lung cancer [ICD9: 162; ICD10:C33-C34] Approved [556264]
Company
Bristol-Myers Squibb
Target and Pathway
Target(s) PD-1 Target Info Modulator [533123]
KEGG Pathway Cell adhesion molecules (CAMs)
T cell receptor signaling pathway
Reactome PD-1 signaling
WikiPathways T-Cell Receptor and Co-stimulatory Signaling
Costimulation by the CD28 family
References
Ref 542358(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7335).
Ref 551486Nivolumab, a Novel Anti??D-1 Monoclonal Antibody for the Treatment of Solid and Hematologic Malignancies (Personalized Medicine in Oncology). Emma Thornton. Anti-PD-1 Therapy. June 2014
Ref 556264Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
Ref 5331232014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.